The ANTES B+ Study: An Open-label, Pragmatic, Randomized, Controlled Trial of Triple Therapy Versus LABA-LAMA Combination to Improve Clinical Control in High Risk GOLD B Patients (B+)
| Registry | NCT06282861, acronym ANTES B+ |
|---|---|
| Status | Terminated - Delays in the opening and activation of participating sites, and a low recruitment rate, with only 48 participants enrolled over the course of one year |
| Phase | Phase 4 |
| Study type | Interventional; randomized, parallel, masking: none, prevention |
| Enrollment | 48 (Actual) |
| Sponsor | Fundacio Privada Mon Clinic Barcelona (Other); collaborators: GlaxoSmithKline |
| Conditions | Chronic Obstructive Pulmonary Disease |
| Interventions | Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Brimica, Duaklir, Ultibro, Ulunar, Xoterna, Anoro, Laventair, Spiolto Respimat, Yanimo, Foradil, Broncoral, Formoterol stada, Oxis, Formatris, Formoterol Aldo, Onbrez, Oslif, Hirobriz, Striverdi, Beglan, Betamican, Inaspir, Serevent, Soltel, Eklira, Bretaris, Seebri, Tovanor, Enurev, Spiriva, Tavulus, Sirkava, Braltus, Gregal, Incruse, Rolufta (Drug) |
| Dates | start 2024-02-29, primary completion 2025-01-23, completion 2025-01-23, first posted 2024-02-28, last updated 2025-08-14 |
| Locations | 1 site in Spain |
Related Papers Related Patents Related Grants Related Experts
All trials for Chronic Obstructive Pulmonary Disease All trials of Trelegy Ellipta 100/62.5/25Mcg Inh 30D All trials of Brimica
Current guidelines recommend initial treatment with dual long-acting bronchodilator therapy (LABA-LAMA) in patients with Chronic Obstructive Pulmonary Disease (COPD) of group B (defined by CAT≥10 and none or 1 moderate exacerbation). However, the investigators hypothesize that there is a subgroup of B patients (B+) at a particularly high risk for poor clinical control, characterized by the following:
* 1 moderate exacerbation in the previous year
* CAT≥10 despite current treatment with LABA -LAMA
* Blood eosinophil levels of ≥150 cells/ml
the investigators further hypothesize that B+ patients could benefit from triple therapy treatment (LABA-LAMA + Inhaled Corticosteroids). Therefore, the main goal of this clinical trial is to compare the efficacy of Trelegy (triple therapy) in improving clinical control in GOLD B+ patients with chronic obstructive disease when compared to standard double therapy (LABA -LAMA).
The clinical control is a validated composite endpoint that includes two domains, the patient's stability, and the impact of the disease.
1028 patients will be randomly allocated to receive either the standard therapy or Trelegy and will be monitored by the investigators for 1 year in 2 on-site visits + 2 remote visits.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Trelegy | Experimental | Drug: Trelegy Ellipta 100/62.5/25Mcg Inh 30D | Trelegy commercial product. 1 inhalation daily for 12 months |
| LABA-LAMA | Active comparator | Drug: Brimica; Drug: Duaklir; Drug: Ultibro; Drug: Ulunar; Drug: Xoterna; Drug: Anoro; Drug: Laventair; Drug: Spiolto Respimat; Drug: Yanimo; Drug: Foradil; Drug: Broncoral; Drug: Formoterol stada; Drug: Oxis; Drug: Formatris; Drug: Formoterol Aldo; Drug: Onbrez; Drug: Oslif; Drug: Hirobriz; Drug: Striverdi; Drug: Beglan; Drug: Betamican; Drug: Inaspir; Drug: Serevent; Drug: Soltel; Drug: Eklira; Drug: Bretaris; Drug: Seebri; Drug: Tovanor; Drug: Enurev; Drug: Spiriva; Drug: Tavulus; Drug: Sirkava; Drug: Braltus; Drug: Gregal; Drug: Incruse; Drug: Rolufta | Any LABA-LAMA combination approved in Spain is accepted. To be used according to product specifications for 12 months. |
Sex: All, ages: 40 Years to 80 Years
Inclusion Criteria: * Female or male * 40-80 yrs. of age * Current/former smokers ≥10 pack-year * Diagnosis of COPD according to GOLD 2023 (post-bronchodilator(BD) FEV1/FVC<0.7 in the appropriate clinical context) with FEV1 post-BD 30-70% of the reference value * B+ phenotype * CAT≥10 despite being on LABA-LAMA for ≥3 months, and * 1 moderate ECOPD in the previous year (treated with a short course of oral steroids and/or antibiotics), and * ≥150 blood Eos/ μL (as determined by a single Eos measurement in the previous 12 months available in the medical record of the patient) * A signed and dated written informed consent prior to study participation. Exclusion Criteria: * GOLD E (≥2 moderate or 1 severe ECOPD in the previous year) * ICS treatment (or oral steroid for whatever reason) during the last 8 weeks (10) * ECOPD during the last 8 weeks * Current diagnosis of asthma or documented history of asthma in the medical record of the patient according to the 2023 Global Initiative for Asthma (GINA) guidelines or other accepted guidelines * Other concomitant respiratory disease (e.g., bronchiectasis, lung fibrosis, lung neoplasm) * Use of domiciliary long-term oxygen therapy or non-invasive ventilation * Alpha-1 antitrypsin deficiency * Unstable or life-threatening cardiac disease, including: * Myocardial infarction or unstable angina in the last 6 months * Unstable or life-threatening cardiac arrhythmia requiring intervention in the last 3 months. * New York Heart Association (NYHA) Class IV Heart failure. * Participation on Pulmonary Rehabilitation Program within 4 weeks prior to Screening or subjects who plan to enter the acute phase of a Pulmonary Rehabilitation Program during the study. * Long term antibiotic therapy (antibiotics are allowed for the short-term treatment of an exacerbation or for short term treatment of other acute infections during the study). * Systemic, oral, parenteral corticosteroids used for COPD and/or other diseases in the 8 weeks before entering in the study (oral/systemic corticosteroids may be used to treat COPD exacerbations during the study). * Active neoplasm * Life expectancy < 1 yr. * Current participation in other RCTs (randomized clinical trial) * Non-compliance: subjects at risk of non-compliance, or unable to comply with the study procedures. * Any disease, disability, or geographic location that would limit compliance for scheduled visits. * Known allergy to Trelegy® components (vilanterol, umeclidinium and/or fluticasone furoate) or inability to use the Ellipta® device. * Women who are pregnant or lactating or are planning to become pregnant during the study.
| Facility | City | Country | Status |
|---|---|---|---|
| Hospital Clínic Barcelona | Barcelona, Catalonia | Spain |
NIH grants: 2023